Study finds TBS as independent contributor to fracture risk assessment

One of the most recent and extensively studied determinants of fracture risk is trabecular bone score (TBS). TBS, which is assessed by lumbar spine dual-energy X-ray absorptiometry (DXA) imaging, provides information about the micro-architectural deterioration of bone tissue. Previous studies have shown that TBS predicts fracture in postmenopausal women and older men. TBS is currently used in conjunction with BMD values to enhance the predictive ability of the widely used Fracture Risk Assessment tool (FRAX), a calculator used to assess an individual's 10-year risk of major osteoporotic fracture.

In the largest such study to date, a team of international researchers have now validated the predictive ability of TBS using individual-level data of 17,809 men and women from 14 studies worldwide. They aimed to validate the contribution of TBS to fracture risk prediction, independent of FRAX, and to examine the impact of applying TBS adjustment to FRAX probabilities.

The study authors found that:

  • TBS was consistently an independent contributor to the assessment of fracture risk and that the relationship with other risk factors was robust across sex, diverse races, fracture incidences, and geographical regions.
  • The combination of TBS with the clinical risk factors (including BMD) showed enhanced gradients of risk for hip and non-hip major osteoporotic fractures compared with TBS or the FRAX risk factors alone.

Co-author Professor John A Kanis, Emeritus Professor in Human Metabolism, University of Sheffield, stated, "The findings of this study support the use of TBS, not only as a standalone assessment of fracture risk but also, more importantly, as an independent contributor to a more global risk assessment that could permit its use alongside established risk assessment tools such as FRAX."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Clinical trial finds pomalidomide effective for treating rare bleeding disorder